ANTI-GD2 MONOCLONAL ANTIBODY 3F8

Summary

Anti-Gd2 Monoclonal Antibody 3F8 (CHEMBL2109418) is a phase-3 clinical-stage unknown; indicated across 5 conditions including neuroblastoma and age-related macular degeneration.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109418
Name	ANTI-GD2 MONOCLONAL ANTIBODY 3F8
Type	Unknown
Max phase	3

Also known as: 3f8, Anti-gd2 monoclonal antibody 3f8, Mab-3f8, ANTI-GD2 MONOCLONAL ANTIBODY 3F8

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuroblastoma	2	MONDO:0005072	EFO:0000621
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
osteosarcoma	1	MONDO:0009807	EFO:0000637
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00969722	PHASE2	TERMINATED	A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
NCT01183429	PHASE2	COMPLETED	3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
NCT01183884	PHASE2	TERMINATED	3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
NCT01183897	PHASE2	COMPLETED	3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).